Bicycle Therapeutics plc American Depositary Shares (BCYC) is a publicly traded Healthcare sector company. As of October 6, 2026, BCYC trades at $3.79 with a market cap of $280.67M and a P/E ratio of -1.17. BCYC moved -5.74% today. Year to date, BCYC is -43.26%; over the trailing twelve months it is -53.95%. Its 52-week range spans $3.33 to $13.11. Analyst consensus is buy with an average price target of $9.25. Rallies surfaces BCYC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bicycle Therapeutics COO Jennifer Scott Perry reports $5,137 ordinary share disposal: COO Jennifer Scott Perry reported selling 1,500 Bicycle Therapeutics ordinary shares on Oct. 2 and Oct. 5, 2026, for a reported $5,137. The sales were priced at $3.47, $3.56 and $3.78 per share, and her reported holding afterward was 89,552 shares.
| Metric | Value |
|---|---|
| Price | $3.79 |
| Market Cap | $280.67M |
| P/E Ratio | -1.17 |
| EPS | $-2.90 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.11 |
| 52-Week Low | $3.33 |
| Volume | 598.09K |
| Avg Volume | 0 |
| Revenue (TTM) | $35.27M |
| Net Income | $-169.03M |
| Gross Margin | 0.00% |
6 analysts cover BCYC: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.25.